Mira Pharmaceuticals Inc (MIRA) 13F Positioning & Ownership Changes (Q2 2026)

MIRA ranks #7804 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

26 institutions disclose a position in MIRA, but none treat it as a major bet — even Cross Staff Investments Inc, its most concentrated holder, allocates just 0.2% of its own portfolio to it.

Cross Staff Investments Inc has trimmed its MIRA position for two straight quarters, cutting it by $202.5K while still holding $340.2K.

MIRA reported a net loss of $10.4M in its latest fiscal year.

• Not yet profitable — net loss of $10.4M in the latest fiscal year
• Net income declined year over year, from -$7.9M to -$10.4M
• Operating cash flow was negative, using $4.7M in cash
• Current ratio of 15.75x — enough short-term assets to cover short-term liabilities
• Liabilities run 167.40x equity — a highly leveraged balance sheet worth noting